Pharmaceutical

Image

Middle East and Africa Inherited Retinal Diseases Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Mar 2022
  • MEA
  • 350 Pages
  • No of Tables: 124
  • No of Figures: 37

Middle East and Africa Inherited Retinal Diseases Market, By Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), By Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender) Industry Trends and Forecast to 2029.

Middle East and Africa Inherited Retinal Diseases Market

Market Analysis and Insights : Middle East and Africa Inherited Retinal Diseases Market

Inherited retinal diseases-or IRDs-are a group of diseases that can cause severe vision loss or even blindness. Each IRD is caused by at least one gene that is not working as it should. IRDs can affect individuals of all ages, can progress at different rates, and are rare. However, many are degenerative, which means that the symptoms of the disease will get worse over time. Common types of IRDs include Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa, Choroideremia, Stargardt’s Disease, and Achromatopsia. The goal of gene therapy is to correct or compensate for the faulty gene. IRDs are especially strong candidates for gene therapy treatments, due to the retina’s unique physical makeup. Compared to other organs of the body, the eye is small and easy to access for treatment administration. However, certain areas of the body are immune privileged, which means that the normal immune response isn’t as active. This is typically in areas of our bodies that are very important, and may become damaged if swelling or inflammation occurs. This means that anything that is implanted into the eye-a cell with a corrected gene, for instance-is less likely to be rejected.

The diagnosis and treatment of inherited retinal diseases consist of various techniques that allow diagnosis of inherited retinal disease after the approval of the product. The treatment for the disease is recently approved which support the market growth.

The inherited retinal diseases is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the inherited retinal diseases market will grow at a CAGR of 5.7% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), By Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender)

Countries Covered

Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA)

Market Players Covered

Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies

Inherited Retinal Diseases Market Dynamics

Drivers

  • Increase in the Prevalence of Inherited Retinal Diseases

The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.

  • Increasing in Pipeline Products

As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Middle East and Africa inherited retinal diseases market.High prevalence of genetic conditions

Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.

Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counseling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of  various retinal diseases will result in the expansion of inherited retinal diseases market. 

Opportunities

  • Increase in Government Initiatives Towards Inherited Retinal Disease.

Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.

Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.

Restraints/Challenges

However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.

This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.

Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 0.5% and 0.1%, with a Middle East and Africa IRD caseload in the range of 50,000 individuals.

Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Inherited Retinal Diseases Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

  • In December  2021,, the Middle East Contries such as Saudi Arabia among others have approved the Luxturna therapy.

Middle East and Africa Inherited Retinal Diseases Market

Middle East and Africa Inherited Retinal Diseases Market Scope

The inherited retinal diseases market is segmented into disease type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Disease Type

  • Retinitis Pigmentosa
  •  Stargardt’s Disease 
  •  Achromatopsia
  •  Cone-Rod Dystrophy
  •  Choroideremia
  •  Leber Congenital Amaurosis (LCA) 
  •  Macular Edema
  •  Others

On the basis of type, the inherited retinal diseases market is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others), by type (diagnosis and therapy), end-users (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, others), distribution channel (retail sales and direct tender.

Type

  • Diagnosis
  • Therapy

On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory surgical center
  • Home Healthcare
  • Others

On the basis of end-users, the inherited retinal diseases market is segmented into hopsitals, specialty clinics, ambulatory surgical center, home healthcare and others

Distribution Channel

  • Retail Sales
  • Direct Tender

The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.

Pipeline Analysis

The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.

Inherited Retinal Diseases Market Regional Analysis/Insights

The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.

The countries covered in the inherited retinal diseases market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA).

Saudi Arabia dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Inherited Retinal Diseases Market Share Analysis

The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.

Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson,  IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.

Research Methodology: Middle East and Africa Inherited Retinal Diseases Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report.. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and AfricaVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:

TABLE 2 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 46 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 47 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 SOUTH AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 57 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 58 SOUTH AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 SAUDI ARABIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 SAUDI ARABIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 SAUDI ARABIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 SAUDI ARABIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 72 U.A.E. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 73 U.A.E. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 U.A.E. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 U.A.E. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 U.A.E. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 U.A.E. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 U.A.E. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 U.A.E. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 U.A.E. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 U.A.E. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 U.A.E. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 U.A.E. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 U.A.E. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 ISRAEL INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 86 ISRAEL INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 ISRAEL THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 ISRAEL NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 ISRAEL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 ISRAEL CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 ISRAEL RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 ISRAEL VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 ISRAEL CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 ISRAEL INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 ISRAEL INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 ISRAEL RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 98 EGYPT INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 99 EGYPT INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 EGYPT THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 EGYPT NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 EGYPT DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 EGYPT CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 EGYPT RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 EGYPT ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 EGYPT VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 EGYPT CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 EGYPT INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 EGYPT INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 110 EGYPT RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 KUWAIT INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 112 KUWAIT INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 KUWAIT THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 KUWAIT NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 KUWAIT DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 KUWAIT CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 KUWAIT RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 KUWAIT VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 KUWAIT CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 KUWAIT INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 122 KUWAIT INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 123 KUWAIT RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 124 REST OF MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Middle East and Africa Inherited Retinal Diseases Market will be projected to grow at a CAGR of 5.7% during the forecast period of 2022 to 2029.
Increase in the Prevalence of Inherited Retinal Diseases, and Increasing in Pipeline Products are flourishing the growth of the Middle East and Africa Inherited Retinal Diseases Market.
The major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
Lack of enough qualified professionals and complications involved with the disease are poised to restrict the Middle East and Africa Inherited Retinal Diseases Market growth.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials